Extended Data Table 1 ∣.
Demographics of participants and vaccine side effects
| Variable | SARS-CoV-2 mRNA vaccination |
Convalescent (N=13) N (%) |
||||
|---|---|---|---|---|---|---|
| Total (N=43) N (%) |
Blood (N=42) N (%) |
Lymph node (N=15) N (%) |
Bone marrow (N=11) N (%) |
Variable | ||
| Age (median [range]) | 38 (28-73) | 37.5 (28-73) | 37 (28-52) | 36 (28-48) | Age (median [range]) | 50 (21-69) |
| sex | sex | |||||
| Female | 21 (48.8) | 20 (47.6) | 7 (53.8) | 6 (54.5) | female | 23 (47.9) |
| Male | 22 (51.2) | 22 (52.4) | 6 (46.2) | 5 (45.5) | Male | 25 (52.1) |
| Race | Race/Ethnicity | |||||
| White | 34 (79.1) | 34 (81) | 12 (80) | 11 (100) | White | 47 (97.9) |
| Black | 6 (14) | 6 (14.3) | 2 (13.3) | 0 (0) | Black | 0 (0) |
| Asian | 1 (2.3) | 0 (0) | 1 (6.7) | 0 (0) | Asian | 1 (2.1) |
| Other | 2 (4.7) | 2 (4.8) | 0 (0) | 0 (0) | Hispanic | 0 (0) |
| Ethnicity | ||||||
| Not of Hispanic, Latinx, or Spanish origin | 41 (95.3) | 40 (95.2) | 14 (93.3) | 10 (90.9) | ||
| Hispanic, Latinx, Spanish origin | 2 (4.7) | 2 (4.8) | 1 (6.7) | 1 (9.1) | ||
| BMI (media [range]) | 26.8 (21.4-67.4) | 26.9 (21.4-67.4) | 24.1 (21.4-40.1) | 23.9 (21.4-40.1) | ||
| Comorbidities | Comorbidities | |||||
| Lung disease | 1 (2.3) | 1 (2.4) | 0 (0) | 0 (0) | Asthma | 10 (20.8) |
| Diabetes mellitus | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Other lung disease | 0 (0) |
| Hypertension | 7 (16.3) | 6 (14.3) | 2 (13.3) | 1 (9.1) | Heart disease | 0 (0) |
| Cardiovascular | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Hypertension | 7 (14.6) |
| Liver disease | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Diabetes mellitus | 3 (6.3) |
| Chronic kidney disease | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Cancer | 6 (12.5) |
| Cancer on chemotherapy | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Autoimmune disease | 4 (8.3) |
| Hematological malignancy | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Hyperlipidaemia | 2 (4.2) |
| Pregnancy | 0 (0) | 0 (0) | 0 (0) | 0 (0) | GERD | 5 (10.4) |
| Neurological | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Other | 16 (33.3) |
| HIV | 0 (0) | 0 (0) | 0 (0) | 0 (0) | Solid Organ Transplant | 1 (2.1) |
| Hyperlipidemia | 1 (2.3) | 1 (2.4) | 0 (0) | 0 (0) | ||
| Gastroesophageal reflux disease | - | - | - | - | ||
| Autoimmune disease | - | - | - | - | ||
| Solid organ transplant recipient | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Bone marrow transplant recipient | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
| Confirmed SARS-CoV-2 infection | 13 (30.2) | 13 (31) | 0 (0) | 0 (0) | Hospitalized for treatment of COVID-19 | 3 (6.3) |
| Time from SARS-CoV-2 infection to baseline visit in days (median [range]) | 234 (70-370) | 234 (70-370) | - | - | ||
| Variable | Total N=43 N (%) |
Total N=43 N (%) |
|---|---|---|
| First dose | Second dose | |
| None | 2 (4.7) | 0 (0) |
| Chills | 9 (20.9) | 18 (41.9) |
| Fever | 6 (14) | 12 (27.9) |
| Headache | 10 (23.3) | 16 (37.2) |
| Injection site pain/redness/swelling | 37 (86) | 39 (90.7) |
| Muscle or joint pain | 10 (23.3) | 25 (58.1) |
| Fatigue | 13 (30.2) | 27 (62.8) |
| Duration of side effects in hours (median | ||
| Chills | 18 (6-72) | 24 (0.2-48) |
| Fever | 8 (3-72) | 30 (1-48) |
| Headache | 36 (6-120) | 24 (4-72) |
| Injection site pain | 48 (0.2-168) | 48 (2-144) |
| Muscle or joint pain | 24 (3-72) | 24 (1-48) |
| Fatigue | 48 (12-120) | 24 (3-144) |